Search in the Abstract Database

Abstracts Search 2014

* = Presenting author

P141. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity

A. Schoepfer1, T. Schaffer2, F. Seibold3, 1Centre Hospitalier Universitaire Vaudois, Gastroenterology, Lausanne, Switzerland, 2University of Bern, Department of Clinical Research, Bern, Switzerland, 3University Hospital Bern, Gastroenterology and Hepatology, Bern, Switzerland


Ficolin-2 is an acute phase reactant produced by the liver and targeted to recognize N-acetyl-glucosamine which is present in bacterial and fungal cell walls. We recently showed that ficolin-2 serum levels were significantly higher in Crohn's disease (CD) patients compared to healthy controls. Of note, no difference was found regarding serum ficolin-2 levels when comparing patients with ulcerative colitis to healthy controls. We aimed to evaluate serum ficolin-2 concentrations in CD patients regarding their correlation with endoscopic severity and to compare them with clinical activity, fecal calprotectin, and CRP.


Patients provided fecal and blood samples before undergoing ileo-colonoscopy. Disease activity was scored clinically according to the Harvey–Bradshaw Index (HBI) and endoscopically according to the simplified endoscopic score for CD (SES-CD). Ficolin-2 serum levels and fecal calprotectin levels were measured by ELISA.


A total of 136 CD patients were prospectively included (mean age at inclusion 41.5±15.4 years, 37.5% females). Median HBI was 3 [2–6] points, median SES-CD was 5 [2–8], median fecal calprotectin was 300 [120–703] µg/g, and median serum ficolin-2 was 2.69 [2.02–3.83] µg/mL. The SES-CD score correlated significantly with fecal calprotectin levels (r = 0.639, p < 0.001), CRP (r = 0.444, p < 0.001), and the HBI (r = 0.363, p < 0.001), whereas only a weak correlation was found with ficolin-2 serum levels (r = 0.144, p = 0.094). Ficolin-2 serum levels were higher in CD patients with mild endoscopic disease compared to patients in endoscopic remission (p = 0.021) but no difference in ficolin-2 serum levels was found between patients with mild, moderate, and severe endoscopic disease.


Ficolin-2 serum levels correlate worse with endoscopic CD activity when compared to fecal calprotectin, CRP or Harvey–Bradshaw index. Ficolin-2 serum levels will probably not have a future role as biomarkers to monitor endoscopic CD activity.